Evidence map›Paper›PMID 33459658›Full record

Observational studyJournal of neuromuscular diseases2021

Results from a 3-year Non-interventional, Observational Disease Monitoring Program in Adults with GNE Myopathy.

Hanns Lochmüller, Anthony Behin, Ivailo Tournev, Mark Tarnopolsky, Rita Horváth, Oksana Pogoryelova, Jinay Shah, Tony Koutsoukos, Alison Skrinar, Emil Kakkis and 2 more

Open access · bronzeAbstract readObservational Study
In one paragraph

Observational study in Journal of neuromuscular diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Effects of a homozygous missense mutation in theZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025
    Article
  5. Article
  6. Observational
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Hanns LochmüllerInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Anthony BehinAPHP, Centre de référence de pathologie neuromusculaire, Institut de Myologie, Groupe Hospitalier Pitié-Salpetrière, Paris, France.
Ivailo TournevExpert Center of Genetic Neurologic and Metabolic Disorders, University Hospital Aleksandrovska; Department of Neurology, Medical University - Sofia, Sofia, Bulgaria, Department of Cognitive Science and Psychology, New Bulgarian University, Sofia.
Mark TarnopolskyMcMaster University Medical Center, Department of Pediatrics, Neuromuscular and Neurometabolic Clinic, Hamilton, ON, Canada.
Rita HorváthInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Oksana PogoryelovaInstitute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
Jinay ShahUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Tony KoutsoukosUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Alison SkrinarUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Emil KakkisUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Camille L BedrosianUltragenyx Pharmaceutical Inc., Novato, CA, USA.
Tahseen MozaffarUniversity of California Irvine, Orange, CA, USA.
Ultragenyx Pharmaceutical (United States) · USNewcastle University · GBAssistance Publique – Hôpitaux de Paris · FRMcMaster University Medical Centre · CANew Bulgarian University · BGUniversity of California, Irvine · US

Funding

Medical Research Council G1000848Medical Research Council MR/N010035/1Medical Research Council MR/N025431/1Medical Research Council MR/N025431/2Medical Research Council MR/V009346/1
6 · The paper itself

Abstract

backgroundGNE myopathy is a rare, autosomal recessive, muscle disease caused by mutations in GNE and is characterized by rimmed vacuoles on muscle biopsy and progressive distal to proximal muscle weakness.

objectiveInvestigate the clinical presentation and progression of GNE myopathy.

methodsThe GNE Myopathy Disease Monitoring Program was an international, prospective, observational study in subjects with GNE myopathy. Muscle strength was assessed with hand-held dynamometry (HHD), with upper extremity (UE) and lower extremity (LE) composite scores reflecting upper and lower extremity muscle groups, respectively. The GNE myopathy-Functional Activity Scale (GNEM-FAS) was used to further assess impairment in mobility, upper extremity function, and self-care.

resultsEighty-seven of 101 enrolled subjects completed the trial until study closure by the sponsor; 60 completed 36 months. Mean (SD) HHD UE composite score decreased from 34.3 kg (32.0) at baseline to 29.4 kg (32.6) kg at month 36 (LS mean change [95%CI]: -3.8 kg [-5.9, -1.7]; P = 0.0005). Mean (SD) HHD LE composite score decreased from 32.0 kg (34.1) at baseline to 25.5 kg (31.2) at month 36 (LS mean change [95%CI]: -4.9 [-7.7, -2.2]; P = 0.0005). GNEM-FAS scores were more severe at baseline in subjects who walked <200 meters versus ≥200 meters in 6 minutes; in both groups, GNEM-FAS total, mobility, UE, and self-care scores decreased from baseline through month 36.

conclusionsThese findings demonstrate progressive decline in muscle strength in GNE myopathy and provide insight into the appropriate tools to detect clinically meaningful changes in future GNE myopathy interventional trials.

Indexed as

AdultBulgariaDistal MyopathiesFemaleHumansLower ExtremityMaleMiddle AgedMuscle, SkeletalMuscle StrengthMuscle WeaknessProspective StudiesYoung Adultmuscle weaknessmuscular diseasesMyopathiesN-acetylneuraminic acid

Identifiers

PMID33459658
PMCPMC8075380
OpenAlexW3121039272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.